Filtered By:
Source: Cancer Control
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 117 results found since Jan 2013.
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
CONCLUSIONS: Cumulatively, these results support the combination of ramucirumab plus docetaxel as an effective and safe subsequent therapy for the treatment of patients with metastatic NSCLC with disease progression irrespective of previous ICI treatment.PMID:37731641 | PMC:PMC10507469 | DOI:10.3389/fonc.2023.1247879
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Edward B Garon Carla Visseren-Grul Maria Teresa Rizzo Tarun Puri Suresh Chenji Martin Reck Source Type: research
Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study
CONCLUSIONS: An increasing proportion of patients received systemic treatment during the period 2010-18. However, less than 50% of patients in our study received systemic treatment. In accordance with updated guidelines, Docetaxel was introduced after 2015 with an increasing proportion of patients receiving systemic treatment as mHSPC. Further studies should address the disease course and treatment given to patients who do not receive systemic treatment.PMID:37725527 | DOI:10.1080/0284186X.2023.2257876
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Anne Holck Stor ås Kaitlyn Tsuruda Sophie Dorothea Foss å Bettina Kulle Andreassen Source Type: research
In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
Conclusions TNBC is a difficult-to-treat oncologic condition, even in an experimental setting. Promising results concerning the addition of targeted therapies (dasatinib) to the conventional cytotoxic ones (docetaxel) have been shown, awaiting further evaluation.PMID:37719631 | PMC:PMC10500968 | DOI:10.7759/cureus.43534
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Ioannis D Passos Dimochristos Papadimitriou Areti Katsouda Georgios E Papavasileiou Apostolos Galatas Panagiotis Tzitzis Alexandra Mpakosi Maria Mironidou-Tzouveleki Source Type: research
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT03732820, and is completed and no longer recruiting.FINDINGS: Between Oct 31, 2018 and March 11, 2020, 1103 patients were screened, of whom 399 were randomly assigned to olaparib plus abiraterone and 397 to placebo plus abiraterone. Median follow-up for overall survival in patients with censored data was 36·6 months (IQR 34·1-40·3) for olaparib plus abiraterone and 36·5 months (33·8-40·3) for placebo plus abiraterone. Median overall survival was 42·1 months (95% CI 38·4-not reached) with olaparib plus abiraterone and 34·7 months (31·0-39·3) with placebo plus a...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Fred Saad Noel W Clarke Mototsugu Oya Neal Shore Giuseppe Procopio Jo ão Daniel Guedes Cagatay Arslan Niven Mehra Francis Parnis Emma Brown Friederike Schl ürmann Jae Young Joung Mikio Sugimoto Oliver Sartor Yu-Zhen Liu Christian Poehlein Laura Barker P Source Type: research
Efficacy and safety of a dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in women with breast cancer: a multicentre, open-label, randomised phase 2 study
CONCLUSIONS: The dexamethasone-based mouthwash safely reduced stomatitis incidence and severity in patients receiving chemotherapy for early breast cancer. Phase 3 clinical trials are warranted for validating our results.PMID:37689451 | DOI:10.1016/j.jebdp.2023.101896
Source: Cancer Control - September 9, 2023 Category: Cancer & Oncology Authors: Sayaka Kuba Shigeto Maeda Kenichiro Shibata Sakiko Soutome Kosho Yamanouchi Megumi Matsumoto Aya Tanaka Michi Morita Toshiko Hatachi Ryota Otsubo Hiroshi Yano Yumiko Kawashita Shuntaro Sato Hideki Taniguchi Kengo Kanetaka Masahiro Umeda Takeshi Nagayasu S Source Type: research
New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & amp; therapeutics
Front Oncol. 2023 Aug 17;13:1193736. doi: 10.3389/fonc.2023.1193736. eCollection 2023.ABSTRACTProstate adenocarcinoma accounts for more than 20% of deaths among males due to cancer. It is the fifth-leading cancer diagnosed in males across the globe. The mortality rate is quite high due to prostate cancer. Despite the fact that advancements in diagnostics and therapeutics have been made, there is a lack of effective drugs. Metabolic pathways are altered due to the triggering of androgen receptor (AR) signaling pathways, and elevated levels of dihydrotestosterone are produced due to defects in AR signaling that accelerate th...
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Neha Thakur Sameer Quazi Bindu Naik Saurabh Kumar Jha Pallavi Singh Source Type: research
Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
CONCLUSIONS: The addition of irinotecan to GTX-C was safe and well tolerated. While the study did not meet its primary objective, the responses were clinically meaningful using a well-tolerated regimen.SIGNIFICANCE: We aimed to optimize the previously reported efficacious regimen of low-dose multiagent therapy with GTX-C for the treatment of metastatic pancreatic ductal adenocarcinoma by adding irinotecan. The primary objective was not met, but GTX-CI was well tolerated. The RR of 57%, median PFS of 8.3 months, median OS of 11 months, and 36-month OS rate of 19% suggest clinical benefit. Further optimization of this regime...
Source: Cancer Control - August 30, 2023 Category: Cancer & Oncology Authors: H Catherine Wilbur Jennifer N Durham Su Jin Lim Katrina Purtell Katherine M Bever Daniel A Laheru Ana De Jesus-Acosta Nilofer S Azad Bradley Wilt Luis A Diaz Dung T Le Hao Wang Source Type: research
Effect of chemotherapy and different chemotherapy regimens on bone health among Chinese breast cancer women in different menstrual status: a self-control study
CONCLUSION: Chemotherapy might induce lumbar vertebrae BMD loss and spine osteoporosis with regimen differences among Chinese BC patients. Calcium/VitD supplementation could improve bone turnover markers, bone metabolism indicators, and bone mineral density. Early interventions on bone health are needed for BC patients during chemotherapy.PMID:37642751 | DOI:10.1007/s00520-023-07960-8
Source: Cancer Control - August 29, 2023 Category: Cancer & Oncology Authors: Bai-Qing Peng Juan Wu Shen Tian Xiu-Quan Qu Xin-Yu Liang Jun-Han Feng Yu-Ling Chen Rui-Ling She Chen-Yu Ma Jing-Yu Song Zhao-Xing Li Zhi-Yu Jiang Kai-Nan Wu Ling-Quan Kong Source Type: research
The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs
Cancer Lett. 2023 Aug 5:216338. doi: 10.1016/j.canlet.2023.216338. Online ahead of print.ABSTRACTGastric cancer (GC) is the fifth most frequent malignancy and the fourth leading cause of worldwide cancer-related death. Despite the usage of multimodal perioperative chemotherapy (pCT), GC progressively gains chemoresistance, thereby, the identification of suitable targets to overcome drug resistance is fundamental. Amongst the potential biomarkers, carbonic anhydrase IX (CAIX) - associated with a poor prognosis of several solid cancers - has gained the most attention. In a cohort of GC patients who received perioperative FLO...
Source: Cancer Control - August 7, 2023 Category: Cancer & Oncology Authors: Elena Andreucci Alessio Biagioni Sara Peri Giampaolo Versienti Fabio Cianchi Fabio Staderini Lorenzo Antonuzzo Claudiu T Supuran Erika Olivo Elisa Pasqualini Luca Messerini Daniela Massi Matteo Lulli Jessica Ruzzolini Silvia Peppicelli Francesca Bianchini Source Type: research
Characterization of tumor microenvironment infiltration and therapeutic responses of cell cycle-related genes' signature in breast cancer
CONCLUSION: The nomogram based on CCG could assess tumour immune micro-environment regulation and therapeutic responses of immunotherapy in BC. Moreover, it may provide novel information on the control of immune micro-environment infiltration in BC and aid in the development of targeted immunotherapy.PMID:37540256 | DOI:10.1007/s00432-023-05198-9
Source: Cancer Control - August 4, 2023 Category: Cancer & Oncology Authors: Huacong Wu Yutao Chen Mengyi Li Zijun Chen Jie Liu Guie Lai Source Type: research
Role of Adverse Events Supervision in Clinical Trials in Neoadjuvant Treatment of
Operable Stage III NSCLC
CONCLUSIONS: Camrelizumab combined with Docetaxel and Cisplatin can be used as a new adjuvant treatment for operable stage III NSCLC. Through the observation and control of AEs, treatment measures can be taken in time to reduce further complications, ensure patient' safety, and ensure the authenticity, scientificity and reliability of clinical trial data.PMID:37488083 | DOI:10.3779/j.issn.1009-3419.2023.102.23
Source: Cancer Control - July 24, 2023 Category: Cancer & Oncology Authors: Yun Zhang Shuang Zhou Wentao Tao Rong Li Source Type: research
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
Exp Hematol Oncol. 2023 Jul 21;12(1):63. doi: 10.1186/s40164-023-00413-2.ABSTRACTTriplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and 5-fluorouracil) regimens were prospectively evaluated in advanced squamous anal cell carcinoma (SCCA), and validated as standard treatments. Even though the high efficacy and good tolerance of DCF regimen were confirmed in 3 independent prospective trials, doublet CP regimen is still recommended in several guidelines based in its better safety profile with similar efficacy compared to CF regimen. We performed a propensity score-adju...
Source: Cancer Control - July 21, 2023 Category: Cancer & Oncology Authors: Stefano Kim V éronique Vendrely Ang élique Saint Thierry Andr é Pauline Vaflard Emmanuelle Samalin Simon Pernot Oliver Bouch é Mustapha Zubir J érôme Desrame Christelle de la Fouchardi ère Denis Smith Fran çois Ghiringhelli Ang élique Vienot Mari Source Type: research
< em > CYP3A < /em > genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
Front Pharmacol. 2023 Jul 4;14:1178421. doi: 10.3389/fphar.2023.1178421. eCollection 2023.ABSTRACTBackground: Taxane-induced peripheral neuropathy (TIPN) is an important cause of premature treatment cessation and dose-limitation in cancer therapy. It also reduces quality of life and survivorship in affected patients. Genetic polymorphisms in the CYP3A family have been investigated but the findings have been inconsistent and contradictory. Methods: A systematic review identified 12 pharmacogenetic studies investigating genetic variation in CYP3A4*22 and CYP3A5*3 and TIPN. In our candidate gene study, 288 eligible participan...
Source: Cancer Control - July 20, 2023 Category: Cancer & Oncology Authors: Laurence McEvoy Joanne Cliff Daniel F Carr Andrea Jorgensen Rosemary Lord Munir Pirmohamed Source Type: research
SNHG1 opposes quiescence and promotes docetaxel sensitivity in prostate cancer
CONCLUSIONS: Overall, these results indicate SNHG1 has complex roles in prostate cancer, as it stimulates cell cycle entry and disease progression, but sensitizes cells to docetaxel treatment.PMID:37464317 | DOI:10.1186/s12885-023-11006-x
Source: Cancer Control - July 18, 2023 Category: Cancer & Oncology Authors: Steven P Zielske Wei Chen Kristina G Ibrahim Frank C Cackowski Source Type: research
Simultaneously metastatic cholangiocarcinoma and small intestine cancer from breast cancer misdiagnosed as primary cholangiocarcinoma: A case report
CONCLUSION: Simultaneous metastatic cholangiocarcinoma and small intestine cancer from breast cancer are rare and the prognosis is extremely poor. Improving preoperative diagnostic accuracy is beneficial to avoid excessive surgical treatment. Treatment should be aimed at relieving biliary obstruction and abdominal pain, and then supplemented with chemotherapy and targeted therapy to control tumor progression and prolong the patient's life.PMID:37449239 | PMC:PMC10336993 | DOI:10.12998/wjcc.v11.i18.4446
Source: Cancer Control - July 14, 2023 Category: Cancer & Oncology Authors: Xin Jiao Mi-Mi Zhai Fang-Zhou Xing Xiao-Ling Wang Source Type: research
